2023 - Research.com Immunology in United States Leader Award
2017 - Warren Alpert Foundation Prize For their collective contributions to the pre-clinical foundation and development of immune checkpoint blockade, a novel form of cancer therapy that has transformed the landscape of cancer treatment.
2016 - AAI-Steinman Award for Human Immunology Research, American Association of Immunologists
Lieping Chen mainly focuses on Immunology, Immune system, Antigen, T cell and Cell biology. His Immunology research includes elements of Cancer and Blockade. The study incorporates disciplines such as Stromal cell and Downregulation and upregulation in addition to Immune system.
His Antigen study incorporates themes from Cancer cell, Inflammation and Monoclonal antibody. His study in T cell is interdisciplinary in nature, drawing from both Cytotoxic T cell, Dendritic cell, Macrophage and Immune tolerance. His Cell biology study combines topics from a wide range of disciplines, such as Receptor, Cytokine, Avidity and Molecular biology.
The scientist’s investigation covers issues in Immunology, Immune system, T cell, Cancer research and Cytotoxic T cell. His study ties his expertise on Cancer together with the subject of Immunology. His Cancer research integrates issues from Melanoma and Oncology.
His research in Immune system intersects with topics in Inflammation, Cytokine and Monoclonal antibody. The T cell study combines topics in areas such as Molecular biology, In vitro, Immune tolerance and Cell biology. His work in Cancer research addresses subjects such as Tumor necrosis factor alpha, which are connected to disciplines such as Interferon gamma.
Lieping Chen spends much of his time researching Cancer research, Immune system, Immunology, Cancer and Immunotherapy. His studies deal with areas such as Cytotoxic T cell, Cell, CD8 and T cell as well as Cancer research. The various areas that Lieping Chen examines in his Immune system study include Receptor, Antibody, Monoclonal antibody and Antigen.
His Immunology study frequently links to other fields, such as In vitro. Lieping Chen focuses mostly in the field of Cancer, narrowing it down to topics relating to Melanoma and, in certain cases, Oncology, Internal medicine, Nivolumab, Immune checkpoint and Blockade. His Immunotherapy study combines topics in areas such as Cancer cell, Lung cancer and Survival analysis.
His scientific interests lie mostly in Immunotherapy, Cancer research, Cancer, Immune system and Immunology. He has included themes like Tumor microenvironment and Lung cancer, Oncology in his Immunotherapy study. Lieping Chen interconnects Cell, T cell, Antigen, Carcinoma and CD3 in the investigation of issues within Cancer research.
His Cancer research incorporates themes from Cytotoxic T cell and Monoclonal antibody. The various areas that Lieping Chen examines in his Immune system study include Antibody and Mediator. Lieping Chen studies Immunology, focusing on Immune privilege in particular.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L. Topalian;F. Stephen Hodi;Julie R. Brahmer;Scott N. Gettinger.
The New England Journal of Medicine (2012)
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.
Tyler J Curiel;George Coukos;Linhua Zou;Xavier Alvarez.
Nature Medicine (2004)
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion
Haidong Dong;Scott E. Strome;Diva R. Salomao;Hideto Tamura.
Nature Medicine (2002)
Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Julie R. Brahmer;Charles G. Drake;Ira Wollner;John D. Powderly.
Journal of Clinical Oncology (2010)
Molecular mechanisms of T cell co-stimulation and co-inhibition
Lieping Chen;Dallas B. Flies;Dallas B. Flies.
Nature Reviews Immunology (2013)
B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion
Haidong Dong;Gefeng Zhu;Koji Tamada;Lieping Chen.
Nature Medicine (1999)
Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy
Janis M Taube;Alison P. Klein;Julie R Brahmer;Haiying Xu.
Clinical Cancer Research (2014)
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
Janis M. Taube;Robert A. Anders;Geoffrey D. Young;Haiying Xu.
Science Translational Medicine (2012)
Inhibitory B7-family molecules in the tumour microenvironment
Weiping Zou;Lieping Chen.
Nature Reviews Immunology (2008)
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
Weiping Zou;Jedd D. Wolchok;Lieping Chen.
Science Translational Medicine (2016)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: